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Interview
Treat now — while we have the drugs
To find out more about the technical and economic options now apparent for infectious disease control, the Bulletin’s Robert Waldgate
talked to David Heymann, WHO’s Executive Director for Communicable Diseases.
Q. Your Infectious diseases report 2002,
prepared with several other UN agencies,
says that this is a truly unique moment —
a moment of heightened awareness and
commitment, and that this is the time to
respond to it with practical programmes.
A. That’s right. It is a unique opportunity
to respond. We have the necessary tools,
and now we have a commitment — not
just to prevent disease, but to treat those
already infected. The six major illnesses
that are responsible for 90% of infectious
disease mortality are acute respiratory
infections, diarrhoeal diseases, AIDS,
malaria, TB and measles. Measles is the
only one of these diseases where infection
can be prevented by a vaccine. However,
perceptions of the importance of vaccines
are shifting. In just the past three years
the international development community
has understood that we can no longer limit
our public health programmes to a strict
focus on vaccination or prevention — we
must also treat people.Wemust cure them,
bring them out of sickness so they can
work, contribute to their economies, and
release themselves from poverty. This
commitment is increasingly evident.
Development agencies are now providing
resources in the form of a Global Fund
with almost US$ 2000million of pledges to
provide developing countries with the
drugs and other commodities needed
to control AIDS, TB and malaria.
Q. You don’t think that this political
commitment has been finally disappoint-
ing, in that Kofi Annan, Secretary General
of theUN,was asking forUS$ 7–10 000mil-
lion a year — but only US$ 800 million
will be disbursed in the first year; while
the President of the USA can ask Congress
without a blink of an eyelid for
US$ 50 000 million for war?
A. I see encouragement on several fronts.
The G8 group of industrialized countries
is committed to reducing the burden of
infectious diseases. The Global Fund was
set up just last month, and the initial
pledges are encouraging. If the interna-
tional community continues to build on
this momentum, and if results can be
demonstrated, then financial support
for the fund will grow. Far from being
disappointing, this is a very exciting time
in public health. The paradigm for health
development has been broadened to
include treatment, and the bilateral and
other development agencies have shown
their willingness to support this broadened
mandate with funds.
Q. And are programmes and governments
in developing countries ready to deliver
on this?
A. Governments are ready to deliver
if they can diversify their health systems
sufficiently and show good stewardship.
This means letting nongovernmental
organizations, the private sector, and other
potential partners work with them to
improve access to drugs and other inter-
ventions, and not keeping them exclusively
in restricted government health facilities.
Q. The report of the Commission on
Macroeconomics and Health, and the
Infectious diseases report 2002, talk about
extremely large sums of money to turn
health systems around — US$ 66 000 mil-
lion a year. That’s not realistic in the
short term, is it? So what will be going on
in the short term?
A. As I said earlier, we have the necessary
tools. In the short term there is great
urgency to use these tools to themaximum.
Existing drugs are gradually becoming
ineffective as antimicrobial resistance
spreads. We have seen simple antibiotics
for simple infections become unusable.
This forces us to resort to much more
expensive antibiotics with many more side-
effects.We face a situation of great urgency
to do the job now with as many partners
as possible. We are confident that if the
proper mix of health services — govern-
ments, civil society, NGOs, the private
sector — is made within countries, much
can be done to scale up immediately. What
Jeffrey Sachs [Chairman of the Commis-
sion on Macroeconomics and Health] sees
as needed is US$ 66 000 million per year.
Of that, governments are expected to
commit about a third. They are expected to
contribute to disease control by commit-
ting resources in the form of staff and other
essential activities. They must be, and
are becoming, active players. Since the
declaration of commitment to reducing
malaria by African Heads of State in Abuja,
Nigeria, two years ago, for example,
several countries have eliminated import
taxes on essentials such as insecticide-
treated bednets to prevent malaria. Now is
the unique moment for the international
community to support developing
countries if we are to get results in a cost-
effective manner. If we wait we will have
to pay more for second line antibiotics.
In some instances we may run out of
antibiotics altogether unless industry in-
creases its rateof researchanddevelopment.
Q. What specific diseases are you
thinking of?
A. The three major killers. With AIDS,
we can prolong life with antiretrovirals
(ARVs), but even so, resistance is devel-
oping. For TB and malaria, resistance is
already a major problem and growing.
Q. Is there a risk of anarchy developing in
ARV sales and distribution, with Africa
becoming an engine of resistance?
A. WHO is currently collecting all
available evidence on the use of ARVs in
preventing mother-to-child-transmission
of HIV, and also in treating persons with
AIDS. That evidence is being collected and
analysed as the basis for sound public
health policies. Those policies are not yet
universal, and it is not yet completely
understood what can and can’t be done in
sub-Saharan Africa. What is clear is that
TB, which is an opportunistic infection in
AIDS, can be successfully treated.We have
the evidence and a strong medical model.
We also know that if you treat TB in AIDS
patients you can prolong lives. You also
prevent transmission of TB to other
people. So TB treatment in AIDS
patients is a very cost-effective means of
prolonging life and halting transmission—
one of those necessary tools we have
right now and need to use with the greatest
urgency. n
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